Oral contraceptive use and measurable cardiovascular risk factors in Korean women aged 20–50 years: The Fourth Korean National Health and Nutrition Examination Survey 2007–2009 (KNHANES IV)

References

• Benagiano G, Bastianelli C, Farris M. Contraception today. Ann N Y Acad Sci 2006;1092:1–32
   PubMed Web of Science ®Google Scholar
• Jick H, Dinan B, Herman R, Rothman KJ. Myocardial infarction and other vascular diseases in young women. Role of estrogens and other factors. JAMA 1978;240:2548–52
   PubMed Web of Science ®Google Scholar
• Stadel BV. Oral contraceptives and cardiovascular disease (second of two parts). N Engl J Med 1981;305:672–7
   PubMed Web of Science ®Google Scholar
• Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med 2003;349:1443–50
   PubMed Web of Science ®Google Scholar
• Lidegaard O, Lokkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012;366:2257–66
   PubMed Web of Science ®Google Scholar
• Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415–28
   PubMed Web of Science ®Google Scholar
• Darney P. Safety and efficacy of a triphasic oral contraceptive containing desogestrel: results of three multicenter trials. Contraception 1993;48:323–37
   PubMed Web of Science ®Google Scholar
• Kovacs L, Bartfai G, Apro G, et al. The effect of the contraceptive pill on blood pressure: a randomized controlled trial of three progestogen-oestrogen combinations in Szeged, Hungary. Contraception 1986;33:69–77
   PubMed Web of Science ®Google Scholar
• Nichols M, Robinson G, Bounds W, et al. Effect of four combined oral contraceptives on blood pressure in the pill-free interval. Contraception 1993;47:367–76
   PubMed Web of Science ®Google Scholar
• Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990;323:1375–81
   PubMed Web of Science ®Google Scholar
• Watanabe RM, Azen CG, Roy S, et al. Defects in carbohydrate metabolism in oral contraceptive users without apparent metabolic risk factors. J Clin Endocrinol Metab 1994;79:1277–283
   PubMed Web of Science ®Google Scholar
• Hurwitz BE, Henry N, Goldberg RB. Long-term oral contraceptive treatment, metabolic syndrome and measures of cardiovascular risk in pre-menopausal women: National Health and Nutrition Examination Survey 1999–2004. Gynecol Endocrinol 2009;25:441–9
   PubMed Web of Science ®Google Scholar
• The fourth Korean National Health and Nutrition Examination Survey: Korea Centers for Disease Control and Prevention (Korea). 2012. Available at http://knhanes.cdc.go.kr/
   Google Scholar
• Kim SH, Kim TH, Hwang HJ. The relationship of physical activity (PA) and walking with sarcopenia in Korean males aged 60 years and older using the Fourth Korean National Health and Nutrition Examination Survey (KNHANES IV-2, 3), 2008–2009. Arch Gerontol Geriatr 2013;56:472--7
   Google Scholar
• Haskell WL, Lee IM, Pate RR, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc 2007;39:1423–34
   PubMed Web of Science ®Google Scholar
• Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640–5
   PubMed Web of Science ®Google Scholar
• Leblanc ES, Laws A. Benefits and risks of third-generation oral contraceptives. J Gen Intern Med 1999;14:625–32
   PubMed Web of Science ®Google Scholar
• Rosenberg L, Palmer JR, Sands MI, et al. Modern oral contraceptives and cardiovascular disease. Am J Obstet Gynecol 1997;177:707–15
   PubMed Web of Science ®Google Scholar
• Boldo A, White WB. Blood pressure effects of the oral contraceptive and postmenopausal hormone therapies. Endocrinol Metab Clin North Am 2011;40:419–32, ix
   PubMed Web of Science ®Google Scholar
• Lopez LM, Grimes DA, Schulz KF. Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev 2012;4:CD006133
   Google Scholar
• Barbagallo M, Dominguez LJ, Licata G, et al. Vascular effects of progesterone: role of cellular calcium regulation. Hypertension 2001;37:142–7
   PubMed Web of Science ®Google Scholar
• Giribela CR, Melo NR, Silva RC, et al. A combined oral contraceptive containing drospirenone changes neither endothelial function nor hemodynamic parameters in healthy young women: a prospective clinical trial. Contraception 2012;86:35–41
   PubMed Web of Science ®Google Scholar
• Berenson AB, Rahman M, Wilkinson G. Effect of injectable and oral contraceptives on serum lipids. Obstet Gynecol 2009;114:786–94
   PubMed Web of Science ®Google Scholar
• Frempong BA, Ricks M, Sen S, Sumner AE. Effect of low-dose oral contraceptives on metabolic risk factors in African-American women. J Clin Endocrinol Metab 2008;93:2097–103
   PubMed Web of Science ®Google Scholar
• Scharnagl H, Petersen G, Nauck M, et al. Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 microg or 30 microg) and levonorgestrel (100 microg or 150 microg) on lipoprotein metabolism. Contraception 2004;69:105–13
   PubMed Web of Science ®Google Scholar
• Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007;115:450–8
   PubMed Web of Science ®Google Scholar
• Sharrett AR, Ballantyne CM, Coady SA, et al. Atherosclerosis Risk in Communities Study G. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001;104:1108–13
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Ferrari S, Tirelli A, et al. Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial. Contraception 2009;79:111–6
   PubMed Web of Science ®Google Scholar
• Kim K, Park H. Effect of oral contraceptive use on lipid profile in Korean women aged 35–55 years. Contraception 2012;86:500–5
   PubMed Web of Science ®Google Scholar
• Krauss RM, Burkman RT Jr. The metabolic impact of oral contraceptives. Am J Obstet Gynecol 1992;167:1177–84
   PubMed Web of Science ®Google Scholar
• Petersen KR. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus. Dan Med Bull 2002;49:43–60
   PubMed Web of Science ®Google Scholar
• Godsland IF, Crook D, Wynn V. Coronary heart disease risk markers in users of low-dose oral contraceptives. J Reprod Med 1991;36:226–37
   PubMed Web of Science ®Google Scholar